Affichage 1 à 10 des 43 essais cliniques
1 | 2 | 3 | 4 | 5 |
ESSAIS CLINIQUES
    No essai
    ClinicalTrials.gov ID
Phase Coordonnateur(rice)
Étude d’augmentation de la dose et d’expansion de la cohorte de phase 1 sur le TSR-042, un anticorps monoclonal anti-PD-1, chez des patients présentant des tumeurs solides avancées
    GARNET
    NCT02715284
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Phase I Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
(EN) A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
    TROPION-PanTumor03
    NCT05489211
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Rodrigo Skowronski
514-934-1934 poste 36275
(EN) A phase 1A/B open-label master study of PF-07799544 as a single-agent and in combination with other targeted agents in participants with advanced solid tumors
    C4901001
    NCT05538130
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
Abdul-Rahman El-Hassan
514-934-1934 poste 35161
(EN) A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
    20190135 (CodeBreak 101)
    NCT04185883
     Actif en recrutement
L'HOTEL-DIEU DE QUEBEC ET CRCEO
Maryse Gingras
418-691-5781
(EN) A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab With Pembrolizumab in Selected Solid Tumors
    KeyForm-010 (MK-4280A-010)
    NCT06036836
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
Maryse Gingras
418-525-4444 poste 67322
(EN) A phase 1A/B open-label master study of PF-07799544 as a single-agent and in combination with other targeted agents in participants with advanced solid tumors
    C4901001
    NCT05538130
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
Geneviève Rochette
418-525-4444 poste 67540
(EN) A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
    ARTISTRY-1
    NCT02799095
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
Maryse Gingras
418-691-5781
(EN) A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
    SGNDV-005
    NCT06003231
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
Maryse Gingras
418-525-4444 poste 67322
Étude de phase II, ouverte et multicentrique, évaluant le lenvatinib combiné au pembrolizumab chez des sujets déjà traités pour des tumeurs solides sélectionnées
    MK-7902-005 (LEAP-005)
    NCT03797326
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
Phase II Véronique Jobin
418-525-4444 poste 15780
(EN) A Phase II Study of Durvalumab Treatment Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity Substudy B: For Continued Treatment (=/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
    IND.238
    NCT03847649
     Actif en recrutement
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
1 | 2 | 3 | 4 | 5 |